儿童复发性急性髓细胞白血病的个体化肿瘤反应测试。

Individual tumor response testing in multiple relapsed acute myeloid leukemia in children.

机构信息

Department of Pediatric Hematology and Oncology, Collegium Medicum, Nicolaus Copernicus University, ul. Curie-Sklodowskiej 9, 85-094 Bydgoszcz, Poland.

出版信息

Anticancer Res. 2013 Mar;33(3):1189-93.

PMID:23482801

Abstract

AIM

The analysis of the individualized tumor response testing (ITRT) at first and subsequent relapse in children with acute myeloid leukemia (AML).

PATIENTS AND METHODS

A total of 76 pediatric AML samples underwent ITRT for up to 21 drugs.

RESULTS

No significant differences between ITRT at first and subsequent relapse were found, and no drug was found, for which significantly higher resistance of myeloblasts was observed at subsequent relapse, when compared to first relapse of AML. For most tested drugs, patients with relapse had higher IRTR than those with de novo AML. The median relative resistance value between patients with relapse and those with de novo diagnosis for all 21 drugs tested was 1.6. Samples of relapsed AML samples were significantly more resistant to: Idarubicin (1.8-fold), etoposide (5.9-fold), cytarabine (1.7-fold), fludarabine (3.7-fold) and busulfan (4.3-fold).

CONCLUSION

ITRT in relapsed AML is higher in comparison to that at initial diagnosis, while no differences in ITRT between first and subsequent relapse of AML were found.

摘要

目的

分析儿童急性髓细胞白血病（AML）初次缓解和后续复发时的个体化肿瘤反应测试（ITRT）。

患者和方法

共有 76 例儿科 AML 样本接受了多达 21 种药物的 ITRT。

结果

初次缓解和后续复发时的 ITRT 无显著差异，与 AML 初次复发相比，后续复发时没有发现哪种药物的髓样白血病细胞明显更耐药。与初诊 AML 患者相比，复发患者对大多数测试药物的 IRTR 更高。对于所有 21 种测试药物，复发患者和初诊患者之间的中位相对耐药值为 1.6。复发 AML 样本对柔红霉素（1.8 倍）、依托泊苷（5.9 倍）、阿糖胞苷（1.7 倍）、氟达拉滨（3.7 倍）和白消安（4.3 倍）的耐药性明显更高。